enkephalin, leucine has been researched along with Atherosclerotic Parkinsonism in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (18.52) | 18.7374 |
| 1990's | 11 (40.74) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capper-Loup, C; Kaelin-Lang, A | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA | 1 |
| Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P | 1 |
| Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J; Tolosa, E | 1 |
| Amalric, M; Breysse, N; Kerkerian-Le Goff, L; Oueslati, A; Salin, P | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Bjørndal, N; Casey, DE; Gerlach, J | 1 |
| Asselin, MC; Côté, PY; Parent, A; Soghomonian, JJ | 1 |
| Björklund, A; Campbell, K; Lindsay, RM; Sauer, H; Wiegand, SJ | 1 |
| Brotchie, JM; Crossman, AR; Maneuf, YP; Mitchell, IJ | 1 |
| Agid, Y; Augood, SJ; Emson, PC; Herrero, MT; Hirsch, EC; Javoy-Agid, F; Luquin, MR; Obeso, JA | 1 |
| Asselin, MC; Côté, PY; Parent, A | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Morissette, M; Soghomonian, JJ | 1 |
| Brotchie, JM; Crossman, AR; Henry, B; Hille, CJ | 1 |
| Drago, J; Finkelstein, DI; Kola, I; Lakso, M; Lawrence, AJ; McManus, JF; Natoli, AL; Padungchaichot, P; Sumarsono, SH; Westphal, H; Wong, JY; Wreford, N | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 1 |
| Decamp, E; Schneider, JS; Wade, T | 1 |
| Schneider, JS; Schroeder, JA | 1 |
| Bordet, R; Ridray, S; Schwartz, JC; Sokoloff, P | 1 |
| Aoyama, S; Borrelli, E; Kase, H | 1 |
| Andrén, PE; Gunne, L; Hurd, YL; Pirker, W; Pontén, H; Tedroff, J | 1 |
| Andersson, M; Cenci, MA; Konradi, C | 1 |
| Borison, RL; Diamond, BI | 1 |
| Augood, SJ; Boyce, S; Clarke, CE; Crossman, AR; Emson, PC; Mitchell, IJ | 1 |
| Chen, S | 1 |
| Lu, ZH | 1 |
| Chen, SD; Pan, GB; Xu, DL; Yu, WC | 1 |
1 review(s) available for enkephalin, leucine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dystonia; Enkephalins; Parkinson Disease, Secondary; Protein Precursors | 1998 |
1 trial(s) available for enkephalin, leucine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Enkephalin, morphine, and naloxone in tardive dyskinesia.
Topics: Aged; Clinical Trials as Topic; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Double-Blind Method; Dyskinesia, Drug-Induced; Endorphins; Enkephalins; Female; Humans; Male; Middle Aged; Morphine; Naloxone; Parkinson Disease, Secondary | 1980 |
25 other study(ies) available for enkephalin, leucine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Locomotor velocity and striatal adaptive gene expression changes of the direct and indirect pathways in Parkinsonian rats.
Topics: Animals; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Enkephalins; Female; Gene Expression; Glutamate Decarboxylase; Hydroxydopamines; Immunohistochemistry; In Situ Hybridization; Motor Activity; Neostriatum; Neural Pathways; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; RNA, Messenger; Signal Transduction; Tyrosine 3-Monooxygenase | 2013 |
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Electron Transport Complex IV; Enkephalins; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2009 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 2002 |
Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cell Count; Dynorphins; Enkephalins; Globus Pallidus; Immunohistochemistry; In Situ Hybridization; Male; Microinjections; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2005 |
Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism.
Topics: Animals; Basal Ganglia; Cerebral Cortex; Denervation; Dopamine Uptake Inhibitors; Electron Transport Complex IV; Enkephalins; Excitatory Amino Acid Antagonists; In Situ Hybridization; Male; Mazindol; Neostriatum; Nerve Net; Neurons; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; RNA, Messenger; Sympatholytics; Tachykinins; Thalamus | 2005 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Enkephalins; Gene Expression; Histocytochemistry; In Situ Hybridization; Parkinson Disease, Secondary; Protein Precursors; Reference Values; RNA, Messenger; Saimiri | 1994 |
Brain-derived neurotrophic factor enhances striatal neuropeptide expression in both the intact and the dopamine-depleted rat striatum.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Injections; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptor, Ciliary Neurotrophic Factor; Receptors, Growth Factor; RNA, Messenger; Tachykinins | 1994 |
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.
Topics: Animals; Bicuculline; Corpus Striatum; Drug Combinations; Efferent Pathways; Enkephalins; gamma-Aminobutyric Acid; Globus Pallidus; Male; Motor Activity; Naloxone; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Synaptic Transmission | 1994 |
Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum.
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Dopamine Agents; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Macaca fascicularis; MPTP Poisoning; Neostriatum; Oligonucleotides, Antisense; Parkinson Disease, Secondary; Protein Precursors; Putamen; RNA, Messenger; Tachykinins | 1995 |
Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Dopamine; Dopamine Agents; Enkephalins; Gene Expression Regulation; Immunohistochemistry; Neostriatum; Neuropeptides; Parkinson Disease, Secondary; Protein Precursors; Saimiri; Tachykinins; Tyrosine 3-Monooxygenase | 1996 |
Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Caudate Nucleus; Dopamine Agonists; Enkephalins; Female; Imidazoles; In Situ Hybridization; Levodopa; Macaca fascicularis; Ovariectomy; Parkinson Disease, Secondary; Protein Precursors; Putamen; Receptors, Dopamine D2; RNA, Messenger; Transcription, Genetic | 1997 |
Targeted expression of a toxin gene to D1 dopamine receptor neurons by cre-mediated site-specific recombination.
Topics: Animals; Apoptosis; Basal Ganglia; Diphtheria Toxin; Enkephalins; Gene Expression Regulation, Enzymologic; Glial Fibrillary Acidic Protein; Gliosis; In Situ Hybridization; In Situ Nick-End Labeling; Integrases; Mice; Mice, Transgenic; Microscopy, Electron; Movement Disorders; Myoclonus; Neurons; Parkinson Disease, Secondary; Phenotype; Radioligand Assay; Receptors, Dopamine D1; RNA, Messenger; Substance P; Viral Proteins | 1998 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1999 |
Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology.
Topics: Acute Disease; Animals; Autoradiography; Behavior, Animal; Chronic Disease; Corpus Striatum; Enkephalins; Gene Expression Regulation; Globus Pallidus; In Situ Hybridization; Macaca fascicularis; Male; Mazindol; Neural Pathways; Parkinson Disease, Secondary; Protein Precursors | 1999 |
Striatal enkephalin gene expression does not reflect parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cats; Caudate Nucleus; Corpus Striatum; Dopamine Agents; Enkephalins; Female; Gene Expression; Male; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Protein Precursors; Recovery of Function; RNA, Messenger | 2000 |
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzazepines; Binding, Competitive; Corpus Striatum; Denervation; Dizocilpine Maleate; Dopamine Agonists; Dopamine Antagonists; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression; Levodopa; Male; Neural Pathways; Neurons; Opioid Peptides; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Sympatholytics; Tachykinins; Tetrahydronaphthalenes; Tritium; Ventral Tegmental Area | 2000 |
Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist.
Topics: Adenosine; Animals; Antihypertensive Agents; Antineoplastic Agents; Enkephalins; Gait; Gene Expression; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Parkinson Disease, Secondary; Phenethylamines; Purinergic P1 Receptor Antagonists; Purines; Radioligand Assay; Receptor, Adenosine A2A; Receptors, Dopamine D2; Receptors, Purinergic P1; RNA, Messenger; Substance P; Tritium | 2000 |
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
Topics: Animals; Autoradiography; Callithrix; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enkephalins; Female; In Situ Hybridization; Injections, Subcutaneous; Levodopa; Ligands; Male; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Protein Precursors; Putamen; RNA, Messenger; Tritium | 2001 |
cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum.
Topics: Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Denervation; DNA; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Routes; Enkephalins; Female; Gene Expression; Levodopa; Oligonucleotides, Antisense; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription Factor AP-1 | 2001 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines; Levodopa; Male; Naloxone; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Rats; Receptors, Opioid; Reserpine; Substantia Nigra | 1978 |
Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; DNA; Dopamine; Enkephalins; Female; Gene Expression Regulation; Macaca; Macaca fascicularis; Male; Neurotoxins; Nucleic Acid Hybridization; Parkinson Disease, Secondary; Pyridines | 1989 |
[Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopamine; Enkephalin, Leucine; Enkephalin, Methionine; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Substantia Nigra | 1990 |
[An experimental study on the contents of enkephalins in the cerebrospinal fluid in rabbits with unilateral destructive lesions produced in the substantia nigra and their relation to the regulation of MIF-1].
Topics: Animals; Enkephalin, Leucine; Enkephalin, Methionine; Female; Male; MSH Release-Inhibiting Hormone; Parkinson Disease, Secondary; Rabbits; Substantia Nigra | 1989 |
Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Brain; Enkephalin, Leucine; Female; Humans; Hydroxydopamines; Levodopa; Male; Middle Aged; MSH Release-Inhibiting Hormone; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Stereotyped Behavior | 1987 |